AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8566261 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms transdermal E2 plus 5 mg medroxyprogesterone acetate (MPA) continuously
Number of subjects: 2
Study 8566261 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogen plus 2.5 mg MPA continuously
Number of subjects: 2
Study 2107241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex-R hyposensitization injections
Number of subjects: 60
Study 2107241 — intervention group
Group type: COMPARATOR
Intervention: Budesonide aqueous nasal steroid spray, 400 micrograms daily
Number of subjects: 60
Study 394282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (Voltarol)
Number of subjects: 60
Study 394282 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (Brufen)
Number of subjects: 60
Study 394282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Diclofenac and Ibuprofen
Number of subjects: 60
Study 31772078 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) using Walkaide
Number of subjects: 200
Study 31772078 — intervention group
Group type: COMPARATOR
Intervention: Usual gait rehabilitation
Number of subjects: 200
Study 28221862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine-based combination (CLARA)
Number of subjects: 221
Study 28221862 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-dose cytarabine (HDAC)
Number of subjects: 221
Study 25888469 — intervention group
Group type: EXPERIMENTAL
Intervention: PFIT‐s
Number of subjects: 66
Study 25888469 — intervention group
Group type: EXPERIMENTAL
Intervention: FSS‐ICU
Number of subjects: 66
Study 25888469 — intervention group
Group type: EXPERIMENTAL
Intervention: IMS
Number of subjects: 66
Study 25888469 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB
Number of subjects: 66
Study 24440809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron + ST36 acupuncture point injection (group C)
Number of subjects: 160
Study 24440809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (group O)
Number of subjects: 160
Study 24440809 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture point injection (group A)
Number of subjects: 160
Study 24440809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 160
Study 22686081 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) + routine therapy
Number of subjects: 68
Study 22686081 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 68
Study 21311490 — intervention group
Group type: EXPERIMENTAL
Intervention: Akatinol memantine
Number of subjects: 41
Study 21311490 — intervention group
Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 41
Study 17761829 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg/day
Number of subjects: 0
Study 17761829 — intervention group
Group type: COMPARATOR
Intervention: Imatinib <600 mg/day
Number of subjects: 0
Study 16212141 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 600
Study 16212141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 11846188 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental continuous oxygen therapy (2 L x min(‐1) via nasal prongs; n = 19)
Number of subjects: 38
Study 11846188 — intervention group
Group type: COMPARATOR
Intervention: No oxygen (n = 19)
Number of subjects: 38
Study 10372934 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day + clarithromycin 250 mg twice daily (group I, n = 22)
Number of subjects: 64
Study 10372934 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day + clarithromycin 250 mg twice daily + amoxycillin 500 mg three times daily (group II, n = 20)
Number of subjects: 64
Study 10372934 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate 120 mg four times daily + amoxycillin 500 mg three times daily + metronidazole 400 mg three times daily (group III, n = 22)
Number of subjects: 64
Study 8839658 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg i.v.
Number of subjects: 10
Study 8839658 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron 5 mg by slow i.v.i.
Number of subjects: 10
Study 8839658 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron by slow i.v.i., followed by 10 mg metoclopramide i.v.
Number of subjects: 10
Study 1733530 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitor (Fastrac)
Number of subjects: 22
Study 1733530 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal CO2 measurement (PETCO2)
Number of subjects: 22
Study 6437892 — intervention group
Group type: EXPERIMENTAL
Intervention: trimipramine 50 mg daily
Number of subjects: 23
Study 6437892 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 30342064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 80
Study 30342064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 28013381 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU cholecalciferol
Number of subjects: 34
Study 28013381 — intervention group
Group type: COMPARATOR
Intervention: 400 IU cholecalciferol
Number of subjects: 34
Study 26256137 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Matricaria chamomilla (Chamomile) oil, applied 3 times/day for 3 weeks
Number of subjects: 0
Study 26256137 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac, applied 3 times/day for 3 weeks
Number of subjects: 0
Study 26256137 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied 3 times/day for 3 weeks
Number of subjects: 0
Study 23708173 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 2982
Study 23708173 — intervention group
Group type: COMPARATOR
Intervention: Primary Stenting
Number of subjects: 2982
Study 21490035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral regurgitation (MR) patients
Number of subjects: 190
Study 21490035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral regurgitation (MR) patients with recurrence
Number of subjects: 190
Study 19713691 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised stretching program (12 sessions)
Number of subjects: 20
Study 19713691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity)
Number of subjects: 20
Study 17267835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingo‐oophorectomy (BSO)
Number of subjects: 161
Study 17267835 — intervention group
Group type: COMPARATOR
Intervention: Ovarian conservation
Number of subjects: 161
Study 15505446 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at rates of 0.1, 0.3, 0.5, 0.7, or 0.9 microg . ml . min
Number of subjects: 18
Study 15505446 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Responsiveness Monitor (ARM)
Number of subjects: 18
Study 15505446 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 18
Study 11273219 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lavage with 0.2% chlorhexidine
Number of subjects: 606
Study 11273219 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lavage with 0.4% chlorhexidine
Number of subjects: 606
Study 11273219 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 606
Study 8263316 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 147
Study 8263316 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 147
Study 8263316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 4030699 — intervention group
Group type: EXPERIMENTAL
Intervention: social skills training plus placebo
Number of subjects: 125
Study 4030699 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐term psychotherapy plus placebo
Number of subjects: 125
Study 4030699 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline alone
Number of subjects: 125
Study 4030699 — intervention group
Group type: EXPERIMENTAL
Intervention: social skills training plus amitriptyline
Number of subjects: 125
Study 31533605 — intervention group
Group type: EXPERIMENTAL
Intervention: HIRT + Ursolic Acid (UA) supplementation
Number of subjects: 22
Study 31533605 — intervention group
Group type: COMPARATOR
Intervention: HIRT + Placebo
Number of subjects: 22
Study 29659201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 1000 mg
Number of subjects: 64
Study 29659201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg
Number of subjects: 64
Study 29659201 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 64
Study 29659201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29071928 — intervention group
Group type: COMPARATOR
Intervention: CANT-0 g group (no Cantharides)
Number of subjects: 120
Study 29071928 — intervention group
Group type: EXPERIMENTAL
Intervention: CANT-1.5 g group
Number of subjects: 120
Study 29071928 — intervention group
Group type: EXPERIMENTAL
Intervention: CANT-3.0 g group
Number of subjects: 120
Study 29071928 — intervention group
Group type: EXPERIMENTAL
Intervention: CANT-1.5 g and CANT-3.0 g groups
Number of subjects: 120
Study 24985376 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy theory health education
Number of subjects: 260
Study 23265344 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (1 g/day)
Number of subjects: 586
Study 23265344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 21211295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1000 mg 3 times per day for 8 weeks
Number of subjects: 60
Study 21211295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ganciclovir ophthalmic gel, 4 times per day, and 0.1% fluorometholone eye drops, 3 times per day (test group)
Number of subjects: 60
Study 21211295 — intervention group
Group type: COMPARATOR
Intervention: Control group (same ophthalmic gel and eye drops without oral ganciclovir)
Number of subjects: 60
Study 21211295 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 21211295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 60
Study 21211295 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 60
Study 18802881 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure electrocautery with hepatic inflow occlusion
Number of subjects: 159
Study 18802881 — intervention group
Group type: COMPARATOR
Intervention: Clamp‐crushing technique alone with hepatic inflow occlusion
Number of subjects: 159
Study 18802881 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure electrocautery
Number of subjects: 159
Study 18802881 — intervention group
Group type: COMPARATOR
Intervention: Clamp‐crushing technique alone
Number of subjects: 159
Study 16642901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + beta tricalcium phosphate (3-TCP) and a collagen membrane
Number of subjects: 7
Study 16642901 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 7
Study 14671522 — intervention group
Group type: EXPERIMENTAL
Intervention: New experimental device (low-profile, fixed-angle plate)
Number of subjects: 2
Study 14671522 — intervention group
Group type: COMPARATOR
Intervention: Association for the Study of Internal Fixation (ASIF) T‐plate
Number of subjects: 2
Study 10803938 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1g/8 h)
Number of subjects: 101
Study 10803938 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g/8 h)
Number of subjects: 101
Study 8628614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg/4 mL)
Number of subjects: 66
Study 8628614 — intervention group
Group type: COMPARATOR
Intervention: Nebulized adrenaline (4 mg/4 mL)
Number of subjects: 66
Study 8628614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study 1320305 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholest (apple-pectin-guar soft-drink) at 1 cup (17 g) every second day
Number of subjects: 33
Study 1320305 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholest (apple-pectin-guar soft-drink) at 1 cup a day
Number of subjects: 33
Study 1320305 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholest (apple-pectin-guar soft-drink) at 2 cups a day
Number of subjects: 33
Study 3535565 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 3 mg kg‐1
Number of subjects: 20
Study 3535565 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 31699003 — intervention group
Group type: COMPARATOR
Intervention: Moderate altitude resistance training (H; 2320 m asl)
Number of subjects: 13
Study 31699003 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic resistance training (N; <700 m asl)
Number of subjects: 13
Study 29492908 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with D2 lymphadenectomy for advanced gastric cancer
Number of subjects: 0
Study 29492908 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 0
Study 29492908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node navigation surgery and related fluorescence molecular imaging techniques
Number of subjects: 0
Study 27040723 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus medical therapy
Number of subjects: 1212
Study 27040723 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1212
Study 24831116 — intervention group
Group type: EXPERIMENTAL
Intervention: Skechers Shape‐Ups
Number of subjects: 16
Study 24831116 — intervention group
Group type: EXPERIMENTAL
Intervention: Reebok Easy Tone
Number of subjects: 16
Study 24831116 — intervention group
Group type: COMPARATOR
Intervention: Standard shoe
Number of subjects: 16
Study 24831116 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 16
Study 22577468 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 303
Study 22577468 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 303
Study 22577468 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 303
Study 21594900 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted preventive intervention integrated within acute medical care
Number of subjects: 85
Study 21594900 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study 19695435 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan with radiation
Number of subjects: 140
Study 19695435 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (Control)
Number of subjects: 140
Study 16468292 — intervention group
Group type: EXPERIMENTAL
Intervention: LP PDL-mediated ALA PDT (14 patients)
Number of subjects: 19
Study 16468292 — intervention group
Group type: COMPARATOR
Intervention: LP PDL-only control (2 patients)
Number of subjects: 19
Study 16468292 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics, oral contraceptives, and topicals control (2 patients)
Number of subjects: 19
Study 15007735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced hygiene practices in DCCs
Number of subjects: 288
Study 15007735 — intervention group
Group type: COMPARATOR
Intervention: Control DCCs (no enhanced hygiene practices)
Number of subjects: 288
Study 11460609 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (containing tetrasodium pyrophosphate, sodium tripolyphosphate, and a copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 73
Study 11460609 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (containing tetrasodium pyrophosphate and a copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 73
Study 9187973 — intervention group
Group type: EXPERIMENTAL
Intervention: Running Training (RT) at 200% of normal training distance
Number of subjects: 11
Study 9187973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross Training (CT) with running (100% normal training) and cycling (100% normal training)
Number of subjects: 11
Study 9187973 — intervention group
Group type: COMPARATOR
Intervention: Control (normal training at 57.5 +/- 10.9 km.wk-1)
Number of subjects: 11
Study 7903132 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac retard 100 mg + Roxatidine 150 mg
Number of subjects: 20
Study 7903132 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac retard 100 mg + Placebo
Number of subjects: 20
Study 3981482 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 0
Study 3981482 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary control over muscle spasming (evidenced by lowered EMG readings)
Number of subjects: 0
Study 30008985 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg/day
Number of subjects: 79
Study 30008985 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg/day
Number of subjects: 79
Study 30008985 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 79
Study 30008985 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 antihistamines (both desloratadine and levocetirizine)
Number of subjects: 79
Study 27833048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - 2-day severe energy restriction (1670-2500 kJ/day) with 5 days of habitual eating for 12 weeks
Number of subjects: 63
Study 27833048 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) - moderate diet (5000-6500 kJ/day) for 12 weeks
Number of subjects: 63
Study 24184313 — intervention group
Group type: EXPERIMENTAL
Intervention: 75mg once-monthly risedronate
Number of subjects: 850
Study 24184313 — intervention group
Group type: COMPARATOR
Intervention: 2.5mg once-daily risedronate
Number of subjects: 850
Study 21450251 — intervention group
Group type: COMPARATOR
Intervention: Internet-based behavioral skills training and knowledge building for NAs
Number of subjects: 86
Study 21450251 — intervention group
Group type: COMPARATOR
Intervention: Internet-based behavioral skills training and knowledge building for LHPs
Number of subjects: 86
Study 20367091 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 36
Study 20367091 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally Positioned Flap (LPF)
Number of subjects: 36
Study 18408387 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AMQ) alone (10 mg AMQ base/kg daily for 3 days)
Number of subjects: 103
Study 18408387 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AMQ) plus chlorpheniramine (CP) (AMQCP) for 7 days (10 mg AMQ base/kg daily for 3 days)
Number of subjects: 103
Study 16485514 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day)
Number of subjects: 0
Study 16485514 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12453126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of four ITI implants with Octa abutments and a U-shaped Dolder gold bar after 2 days.
Number of subjects: 20
Study 12453126 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of four ITI implants with Octa abutments after 3-4 months.
Number of subjects: 20
Study 12453126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants with a U-shaped bar.
Number of subjects: 20
Study 12453126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading method.
Number of subjects: 20
Study 10030287 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus/prednisone
Number of subjects: 208
Study 10030287 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus/prednisone/mycophenolate mofetil
Number of subjects: 208
Study 8719169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure
Number of subjects: 54
Study 8719169 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exposed workers)
Number of subjects: 54
Study 2036244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiethylperazine (6.5 mg p.o every 8 h x 3 days) plus methylprednisolone (250 mg i.v. x 2 doses)
Number of subjects: 46
Study 2036244 — intervention group
Group type: COMPARATOR
Intervention: Thiethylperazine plus placebo
Number of subjects: 46
Study 2036244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiethylperazine plus methylprednisolone
Number of subjects: 46
Study 6790985 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 102
Study 6790985 — intervention group
Group type: COMPARATOR
Intervention: Control (no granulocyte transfusions)
Number of subjects: 102
Study 31036286 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (APR)
Number of subjects: 0
Study 31036286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant (FosAPR)
Number of subjects: 0
Study 28861338 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20
Study 28861338 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 25465217 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR)
Number of subjects: 30
Study 25465217 — intervention group
Group type: COMPARATOR
Intervention: No capsular tension ring (Control group)
Number of subjects: 30
Study 23160261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CYP) with corticosteroids and plasmapheresis
Number of subjects: 41
Study 23160261 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide (CYP) with plasmapheresis and prednisolone (from MEPEX trial)
Number of subjects: 41
Study 23160261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CYP)
Number of subjects: 41
Study 21685706 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise (performed 50 min before fat intake)
Number of subjects: 0
Study 21685706 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial exercise (performed 20 min after fat intake)
Number of subjects: 0
Study 21685706 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study 19841835 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality‐based system delivered via the Internet for motor tasks
Number of subjects: 36